Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial – Frontiers
A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial Frontiers Source: Author: | Date: 2024-04-23 07:00:00 Source: Author: | Date: 2024-04-23 07:00:00
Aldeyra Eyes NDA Resubmission for DED Treatment
Aldeyra Therapeutics announced its clinical development strategy aimed at the resubmission of a New Drug Application (NDA) for its topical ocular 0.25% reproxalap. This investigational RASP modulator is poised for the treatment of dry eye disease, pending approval from the…
Aurion’s First Canadian Dose in Corneal Edema Trial
Aurion Biotech has dosed the first Canadian participant in its phase 1/2 clinical trial, known as ABA-1, CLARA. The trial investigates the efficacy and safety of AURN001, a novel cell therapy aimed at treating corneal edema resulting from corneal endothelial…
Opus Genetics’ LCA5 Therapy Enters Phase 1/2 Trial
Opus Genetics recently completed the first stage of its innovative clinical trial, focusing on a new treatment for patients suffering from Leber congenital amaurosis (LCA) due to biallelic mutations in the LCA5 gene. The trial, which is in the phase…
BlueRock and Foundation Fighting Blindness Partner for IRD Study
BlueRock Therapeutics LP, a clinical-stage cell therapy company and a subsidiary of Bayer, in partnership with Foundation Fighting Blindness, has announced their collaboration to introduce a new cohort to the Foundation’s ‘Uni-Rare natural history study’. This initiative focuses on individuals…
Nanodropper Adaptor Proven Effective in IOP Management
In a pivotal development in the field of ophthalmology, Nanodropper Inc announced that the results from a clinical trial evaluating the Nanodropper® Adaptor have been published in the esteemed journal, Ophthalmology. The study’s findings indicate that there was no clinically…
Minocycline Fails to Halt Progression of Dry AMD
In a recent phase II clinical trial conducted by the National Eye Institute (NEI), part of the National Institutes of Health, the antibiotic minocycline, known for its anti-inflammatory properties, was tested for its efficacy in slowing down the progression of…
Innovent’s nAMD Drug Succeeds in Phase 2 Trial
Innovent Biologics announced that its second Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a high-dose recombinant human VEGFR-Fc-Human CR1 fusion protein injection, has achieved its primary endpoint in treating Chinese subjects with neovascular age-related macular degeneration (nAMD).…
Top 12 Gene Therapies for Eye Diseases and Blindness
In a groundbreaking era of medical research, scientists and clinicians are spearheading novel gene therapies that hold promise for transforming the landscape of eye disease treatment. These cutting-edge interventions address a spectrum of conditions ranging from Usher Syndrome and retinoschisis…
OcuTerra’s Nesvategrast Misses Mark in Diabetic Retinopathy Trial
OcuTerra Therapeutics announced the topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial, evaluating the efficacy of nesvategrast (OTT166). Nesvategrast, an innovative RGD integrin inhibitor formulated as an eye drop, was under investigation for its…